Table 12

Prospective clinical studies using somatostatin or its analogue octreotide in human acute pancreatitis

ReferenceStudy designDrug/dosageNumber of patientsComplicationsMortality
ControlsTreatmentControlsTreatment
Gjorup and colleagues40 RCT,Somatostatin6330% (9/30)42% (14/33)3% (1/30)3% (1/33)
multicentre250 μg/h for 3 days
Luengo and colleagues41 RCTSomatostatin100NANA2% (1/50)2% (1/50)
250 μg/h for 48 h
Beechey-Newman42 OpenOctreotide19NANA0%0%
0.5 μg/kg/h for 10 days
O’Hair and colleagues43 RCTOctreotide 100 μg t.i.d.18010% (9/90)3% (3/90)0%1% (1/90)
s.c. until discharge
Paran and colleagues44 OpenOctreotide 100 μg t.i.d.3874% (14/19)26% (5/19) 31% (6/19)10.5% (2/19)
s.c. for 14 days63% (12/19)37% (7/19)
Fiedler and colleagues45 Case controlledOctreotide 100 μg t.i.d.9387% (47/59)51% (26/39)§ 61% (33/54)26% (10/39)4-150
i.v. for 10 days40% (21/59)18% (7/39)
McKay and colleagues46 RCT,Octreotide 40 μg/h5837% (11/30)53% (15/28)20% (6/30)18% (5/28)
multicentrei.v. for 5 days
Present studyRCT,Octreotide 100 μg t.i.d.30271% (73/103)76% (74/98)16% (16/103)15% (15/98)
multicentres.c. for 7 days
Octreotide 200 μg t.i.d.71% (73/103)72% (73/101)16% (16/103)12% (12/101)
s.c. for 7 days
  • RCT, randomised controlled trial; NA, not assessed.

  • 4-150 p<0.05; sepsis, p=0.004; ARDS, p=0.1; §shock, p<0.05; ARDS, p<0.05.